Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Core Viewpoint - Aldeyra Therapeutics, Inc. announced that the FDA has extended the PDUFA target action date for the reproxalap NDA for dry eye disease treatment to March 16, 2026 [1] Company Summary - Aldeyra Therapeutics is a biotechnology company focused on developing therapies for immune-mediated diseases [1] Regulatory Update - The FDA's extension of the PDUFA target action date indicates a delay in the review process for reproxalap [1]